Anti tubulinα β

Total cell lysates as well as nuclear and cytoplasmic enriched fractions were generated and used in Western Blot analysis as described earlier [9 (link)]. The primary antibodies applied were as follows: anti-P^T202/Y204-ERK1/2, anti-ERK1/2, anti-P^T359/S363-RSK, anti-RSK1/2/3, anti-P^S102-YB-1, anti-P^S112-Bad, anti-Bad, anti-P^S473-AKT, anti-AKT, anti-caspase 3, anti-cleaved caspase 3, anti-cleaved PARP, anti-GAPDH, anti-Tubulinα/β (all Cell Signaling Technology); anti-LaminB (Santa Cruz Biotechnology); anti-YB-1 (Abcam). Immunodetection was carried out as described previously [9 (link)].

EGF was obtained from Peprotech. Anti-Iba1 was obtained from Wako. Anti-S100β was obtained from Abcam and from DAKO, anti-β-galactosidase (β-gal) was obtained from Abcam. Anti-glial fibrillary acid protein (GFAP), anti-phospho (p)-Sema4B, anti-Sema4B, anti-vimentin, anti-tubulin α/β, anti-p-ERK1/2, anti-Ki-67, anti-myc, and anti-NeuN were purchased from Cell Signaling Technology. Anti-bromodeoxyuridine (BrdU; G3G4, developed by S.J. Kaufman, was obtained from the Developmental Studies Hybridoma Bank, which was developed under the auspices of the National Institute of Child Health and Human Development and maintained at the University of Iowa, Department of Biological Sciences, Iowa City, IA). BrdU flow kit was purchased from (BD Biosciences). Secondary antibodies were obtained from Jackson ImmunoResearch. All other reagents were purchased from Sigma.